While specific monoclonal antibodies (trastuzumab) or small molecule inhibitors (lapatinib, neratinib) of HER2 (human epidermal growth factor receptor 2) confer a survival benefit to patients with HER2 + breast cancer, subsets of patients do not benefit from these drugs, and others acquire resistance via multiple mechanisms2. Here, ERBB2 is linked to breast carcinoma.